Preclinical results show potential of AS-100283, a CaMKIIδ inhibitor, for the treatment of β-blocker-resistant arrhythmias
Nov. 14, 2022
Calcium/calmodulin-dependent protein kinase II (CaMKII) is involved in the regulation of calcium and its hyperactivation can lead to cardiac issues, particularly with rhythm and contraction.